Source - LSE Non-Regulatory
RNS Number : 8524K
Cactus Life Sciences
16 April 2024
 

Cactus Life Sciences Announces Appointment of Oliver Dennis as Chairman to Shape the Agency of the Future

Fishawack Health Founder's Deep History in Healthcare Communications Blends Nicely with Global Scientific Communications Agency's Upcoming Buy-and-Build Strategy

PRINCETON, NJ / ACCESSWIRE / April 16, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that Oliver Dennis has joined them as Chairman, to work alongside Co-founder, Anurag Goel.

IMAGE: https://cdn.nwe.io/files/x/a3/94/e69f2ba80f26ba97b986c1005693.jpg

Cactus Life Sciences, headquartered in Princeton, New Jersey was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. "We're delighted to have someone with Oliver's experience of growing businesses join the team," said Anurag. "Cactus Life Sciences is about to undertake an exciting buy and build strategy. And Oliver is the perfect addition with his deep history in healthcare communications having founded Fishawack Health® (now Avalere®)."

During Oliver's tenure at Fishawack, he acquired 17 businesses over 13 years including medical communications and branding agencies, as well as strategic healthcare consultancies and market access and HEOR advisory firms. He led 4 management buy outs to take the business from a start-up to over 1400 people across 22 offices, spanning San Diego to Singapore. Oliver will specifically help shape the future vision for Cactus Life Sciences as the healthcare communications agency partner of the future (strategic, agile, tech-enabled, and outcomes focused) to take on traditional agencies which have lost agility and identity in the pursuit of maximizing profit. He will play an active role in driving the inorganic growth strategy for the business, while pursuing his passion for bringing people together from different businesses and disciplines to collaborate on better outcomes for clients, patients, and our people.

"I've been following Cactus over the last 10 years and they're a great organization. I'm excited to be joining them. They've grown consistently and they have the ambition to become the next generation challenger brand to the traditional players in the market," said Oliver. "This is an opportunity to do something with a greater focus on solving client challenges, improving health outcomes, and nurturing our people."

"Too many companies get to a size where they lose their sense of purpose, values, and forget about individuality. As we work toward transforming Cactus Life Sciences into an agency of the future, we want to ensure that we do so while ensuring that patients and our people are at the core of everything we do," said Elvira D'souza, President of Cactus Life Sciences.

About Cactus Life Sciences (cactuslifesciences.com) Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world─with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes. CACTUS has offices in Princeton, London, Aarhus, Singapore, Beijing, Shanghai, Seoul, Tokyo, and Mumbai.

Contact Information:

Laura Perry 
Vice President of Strategy & Marketing 
laura.perry@cactusglobal.com 
7327121005

SOURCE: Cactus Life Sciences

.

 

View the original press release on newswire.com.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAIFMITMTABBFI
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo